NOTTINGHAM, England--(BUSINESS WIRE)--Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce the appointment of Keith Valentine as the Non-Executive Chair of the Board with immediate effect. Keith joins with over 30 years’ experience in the orthopaedic industry, encompassing various leadership and senior executive positions in marketing, development and operations.
Since May 2015, Keith has served as the Chief Executive Officer and President of SeaSpine, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, where he has successfully expanded the business and delivered significant revenue growth. He joined SeaSpine from NuVasive, a leader in spine technology innovation, where he spent 14 years in various senior roles including President and Chief Operating Officer from 2007 to 2015. Prior to this, he served as Vice President of Marketing at ORATEC Interventions, which was acquired by Smith and Nephew PLC in 2002, and also spent eight years in various roles with Medtronic Sofamor Danek, including as Vice President of Marketing for the Rods division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing.
John von Benecke, CEO of Locate, said: “We are thrilled to welcome Keith to the Locate team. This is an exciting appointment that further demonstrates the momentum we are building as an orthobiologics business. Keith has an amazing pedigree and we are delighted to have attracted someone of his calibre and proven track record to the business. His considerable wealth of experience at some of the sector’s biggest names will be invaluable in supporting Locate Bio as we continue to execute on our strategy of building a world-leading, diversified orthobiologics company.”
Keith Valentine, Non-Executive Chair, said: “I am delighted to be joining the Board of Locate Bio at this exciting stage, and look forward to working with the Company as it continues to progress its differentiated portfolio of best-in-class orthobiologics technologies. There is a significant unmet need for effective orthobiologic products, that provide improved options to surgeons in a range of indications. Locate Bio has an exciting pipeline of innovative products that have real disruptive potential and could improve the lives of the millions of people suffering from debilitating conditions.”
The appointment follows the Company’s recent acquisition of multiple late stage complementary orthobiologics assets from Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, accelerating its route to market and broadening its orthobiologics pipeline. The Company continues to look for additional, complementary acquisitions or in-licencing opportunities that would further broaden its portfolio to provide surgeons with a choice of best-in-class technologies and products that address the current challenges of existing products and meet specific patient driven clinical needs.
About Locate Bio
Locate Bio is an innovative orthobiologics company with a proprietary, regenerative medicine pipeline, delivering exciting orthobiologics products that have great disruptive potential.
Locate Bio’s ambition is to build a world leading, diversified suite of best-in-class technologies that address the performance limitations of existing products and enable orthopaedic surgeons to improve the lives of people suffering from debilitating conditions. Locate Bio’s lead asset in development, is a low dose, controlled release rhBMP-2 spinal fusion product intended for the treatment of lower back pain caused by degenerative disc disease.
Locate Bio is a spin-out from the University of Nottingham and based on the research of Professor Kevin Shakesheff, a world-leading expert in regenerative medicine. The Company is backed by Mercia Asset Management PLC.
To learn more visit: https://www.locatebio.com/